Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 11/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97672 | 1.00 | PDPK1 (0.46) | PDPK1CDK1CDK2TYRATM | |
| SCHEMBL11130951 | 0.83 | SLC5A2 (0.43) | ATMSLC5A1SLC5A2ALDH1A1POLB | |
| SCHEMBL8068087 | 0.83 | CDK1 (0.47) | CDK1CDK2 | |
| SCHEMBL2941560 | 0.83 | ALDH1A1 (0.41) | TYRATMSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL11011378 | 0.83 | FBP1 (0.45) | PDPK1CDK1CDK2 | |
| Ribose (Furanose) SCHEMBL291402 | 0.82 | PDPK1 (0.61) | PDPK1CDK1CDK2CDC7DBF4 | |
| SCHEMBL8059232 | 0.82 | CDK1 (0.46) | CDK1CDK2 | |
| SCHEMBL11133877 | 0.81 | SLC5A2 (0.44) | TYRATMSLC5A1SLC5A2ALDH1A1 | |
| SCHEMBL1963526 | 0.76 | PDPK1 (0.46) | PDPK1ALDH1A1 | |
| Ribose (Furanose) SCHEMBL12542065 | 0.75 | HSD17B10 (0.40) | PDPK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549960-B1 | Topical transdermal method for delivering nutrients through the skin for expedited wound healing and skin rejuvination | NEVILLE PHARMACEUTICAL, INC. (US) | 2017-01-24 | — | — | US | claimed |
| US-9439940-B2 | Topical transdermal method for delivering nutrients through the skin for expeditied wound healing and skin rejuvenation | NEVILLE PHARMACEUTICAL, INC. (US) | 2016-09-13 | — | — | US | claimed |
| US-20160082068-A9 | Topical Transdermal Method for Delivering Nutrients Through the Skin for Expeditied Wound Healing and Skin Rejuvenation | NEVILLE PHARMACEUTICAL, INC. | 2016-03-24 | — | — | US | claimed |
| US-20130022687-A1 | TOPICAL TRANSDERMAL METHOD FOR DELIVERING NUTRIENTS THROUGH THE SKIN FOR EXPEDITED WOUND HEALING | FITZGERALD JR JOHN JAMES (US) | 2013-01-24 | — | — | US | claimed |
| WO-1997021443-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | BALAZOVSKIY MARK BORISOVICH (RU) | 1997-06-19 | — | — | WO | claimed |
| US-4405610-A | INOSINE, LYSINE OROTATE | KRNJEVIC HRVOJE (YU) | 1983-09-20 | — | — | US | claimed |
| US-20250275926-A1 | MULTILAYER FORMULATION COMPRISING MODIFIED TAPIOCA STARCH FOR CONTROLLED-RELEASE OF ACTIVE AGENTS | ACCESS BUSINESS GROUP INT LLC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20240415095-A1 | PET HEALTH AQUEOUS COMPOSITION AND ASSOCIATED CONTAINER | SUSU PETS LLC (US) | 2024-12-19 | — | — | US | disclosed |
| WO-2023205222-A1 | MULTILAYER FORMULATION COMPRISING MODIFIED TAPIOCA STARCH FOR CONTROLLED-RELEASE OF ACTIVE AGENTS | ACCESS BUSINESS GROUP INTERNATIONAL LLC (US) | 2023-10-26 | — | — | WO | disclosed |
| US-20220369592-A1 | Container for an Aqueous Composition | SUSU PETS, LLC (US) | 2022-11-24 | — | — | US | disclosed |
| US-11491175-B2 | Synergistic bioactive compositions for enhancing cellular energy | Celagenex Research (India) Pvt. Ltd. (IN) | 2022-11-08 | — | — | US | disclosed |
| US-20220125815-A1 | SYNERGISTIC BIOACTIVE COMPOSITIONS FOR ENHANCING CELLULAR ENERGY | Celagenex Research (India) Pvt. Ltd. (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11298330-B2 | Magnesium compositions and methods of use | NEUROCENTRIA, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-6251857-B1 | USING OXIDIZED GLUTATHIONE (ALSO KNOWN AS GLUTATHIONE DISULFIDE AND GSSG), DERIVATIVE OR SALT THEREOF; TREATING NEOPLASTIC, INFECTIOUS, HEMATOLOGIC AND IMMUNOLOGIC DISEASES | NOVELOS THERAPEUTICS, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6165979-A | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof | NOVELOS THERAPEUTICS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0869809-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | Balazovsky, Mark Borisovich (RU) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997021444-A9 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | — | 1997-10-30 | — | — | WO | disclosed |
| WO-1997021444-A1 | CYTOKINE AND HEMOPOIETIC FACTOR ENDOGENOUS PRODUCTION ENHANCER AND METHODS OF USE THEREOF | BALAZOVSKY MARK BORISOVICH (RU) | 1997-06-19 | — | — | WO | disclosed |
| WO-1993006119-A1 | DEOXYNUCLEOSIDE DERIVATIVES | THE INSTITUTE OF CANCER RESEARCH (GB) | 1993-04-01 | — | — | WO | disclosed |
| US-4405610-A | INOSINE, LYSINE OROTATE | KRNJEVIC HRVOJE (YU) | 1983-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125815-A1 | SYNERGISTIC BIOACTIVE COMPOSITIONS FOR ENHANCING CELLULAR ENERGY | ATIC, ADORA2A, NT5C2 | PDPK1 1335/4885CDK1 1195/4885CDK2 981/4885 |
| US-20250275926-A1 | MULTILAYER FORMULATION COMPRISING MODIFIED TAPIOCA STARCH FOR CONTROLLED-RELEASE OF ACTIVE AGENTS | SI, AMY1A, GANC | PDPK1 4085/4885CDK1 1280/4885CDK2 3021/4885 |
| US-11491175-B2 | Synergistic bioactive compositions for enhancing cellular energy | ATIC, ADORA2A, NT5C2 | PDPK1 1335/4885CDK1 1195/4885CDK2 981/4885 |
| US-11298330-B2 | Magnesium compositions and methods of use | SLC5A6, SLC6A6, SLC6A5 | PDPK1 4576/4885CDK1 2988/4885CDK2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.